Grant Overview
The European Commission is offering grants under the HORIZON-MISS-2024-CANCER-01-03
call, focused on developing accessible and affordable tests for the early detection of heritable
cancers in European regions. This funding opportunity aims to integrate advanced genetic and
biomarker-based tests into routine healthcare, particularly targeting Central and Eastern
European countries
Funding Details
• Opening date: 18th April 2024
• Closing date: 18th September 2024
• Expected EU Contribution per Project: Between EUR 10 million and EUR 12 million
• Total Indicative Budget: EUR 35 million
• Type of Action: Innovation Actions
Eligibility and Requirements
• Projects must be led by entities with a supportive administrative letter of intent from the
geographical area where the action will be implemented.
• Proposals should reach Technology Readiness Levels (TRL) 5 to 7 by project end.
• Applicants must be compliant with GDPR and address accessibility for individuals in
remote and rural areas.
Objectives and Scope
The initiative seeks to:
• Validate, pilot, and upscale innovative tests for early cancer detection.
• Focus on genetic, multi-omics, or other biomarker-based tests.
• Engage with regional and national healthcare systems to integrate these solutions.
• Address the specific needs of various populations, including stratification by sex,
gender, age, and other determinants.
Key Challenges Addressed
• Increased cancer incidence and mortality across Europe, with significant regional
disparities.
• The need for early detection methods that can be easily implemented within existing
healthcare infrastructures.
Project Activities
• Conduct clinical and socio-economic feasibility studies.
• Co-create testing protocols and procedures with end-users, including healthcare
professionals and citizens.
• Extensively pilot and upscale testing in at least three different EU Member States or
Associated Countries, with a focus on Eastern Europe.
• Collaborate with EIT-Health KIC networks for support in entrepreneurship, education,
and innovation.
Expected Outcomes
Projects funded under this call are expected to lead to:
• More accessible and cost-effective early detection tests for cancers with a heritable
genetic risk.
• Enhanced collaboration between innovators, policymakers, and healthcare providers.
• Improved early detection and treatment outcomes for patients at risk.
Additional Information
Successful proposals will join the 'Prevention and Early Detection' cluster for the EU Mission on
Cancer, contributing to broader EU initiatives through networking and joint activities.
If you are considering applying for this grant and need support with your application, please
contact Inventya for expert advice and assistance.